Literature DB >> 18614667

Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.

Zukile Gqada, Ben Marais, Elizabeth Wasserman, Colleen Bamford, Heidi Orth, George Sakoulas, Warren Rose, Michael J Rybak, Satish Pillai, Jeff Alder, Robert C Moellering, George M Eliopoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18614667      PMCID： PMC2446886          DOI： 10.1128/JCM.00519-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  7 in total

Review 1.  Mechanisms of action of newer antibiotics for Gram-positive pathogens.

Authors:  Robert Ew Hancock
Journal:  Lancet Infect Dis       Date:  2005-04       Impact factor: 25.071

2.  Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.

Authors:  Thomas P Lodise; Peggy S McKinnon; Donald P Levine; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

3.  Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

Authors:  W E Alborn; N E Allen; D A Preston
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

4.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

5.  Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.

Authors:  George Sakoulas; Warren Rose; Michael J Rybak; Satish Pillai; Jeff Alder; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2007-11-14       Impact factor: 5.948

6.  Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.

Authors:  Feng-Yee Chang; James E Peacock; Daniel M Musher; Patricia Triplett; Brent B MacDonald; Joseph M Mylotte; Alice O'Donnell; Marilyn M Wagener; Victor L Yu
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

7.  Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  Pamela A Moise; Davida S Smyth; Nadia El-Fawal; D Ashley Robinson; Patricia N Holden; Alan Forrest; George Sakoulas
Journal:  J Antimicrob Chemother       Date:  2007-11-27       Impact factor: 5.790
  7 in total
  2 in total

1.  VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus.

Authors:  Shrenik Mehta; Arabela X Cuirolo; Konrad B Plata; Sarah Riosa; Jared A Silverman; Aileen Rubio; Roberto R Rosato; Adriana E Rosato
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

2.  Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly E Steed; Celine Vidaillac; Warren E Rose; Patricia Winterfield; Glenn W Kaatz; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.